ABSTRACT
Due to the complex of the ocular structure, the treatment of the posterior eye segment neovascular diseases has been a hot and difficult point in the field of ophthalmic disease and correspongding drug research. The clinical treatment methods for this kind of diseases, such as intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) drugs, are usually costly and have potential side-effects. Researchers have explored a series of treatment methods with better patient compliance, higher drug concentration in the posterior eye segment and better therapeutic effect. In order to research and develop the ideal drugs for the treatment of the posterior eye segment neovascular diseases, we review the main challenges and the advances in drug delivery for the treatment of this kind of diseases in this paper.